140 related articles for article (PubMed ID: 38498297)
21. In the cystoscopic follow-up of non-muscle-invasive transitional cell carcinoma, NMP-22 works for high grades, but unreliable in low grades and upper urinary tract tumors.
Coskuner E; Cevik I; Ozkan A; Dillioglugil O; Akdas A
Int Urol Nephrol; 2012 Jun; 44(3):793-8. PubMed ID: 22371126
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma.
Hayashi Y; Fujita K; Matsuzaki K; Matsushita M; Kawamura N; Koh Y; Nakano K; Wang C; Ishizuya Y; Yamamoto Y; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Uemura M; Imamura R; Takao T; Takada S; Netto GJ; Nonomura N
Cancer Sci; 2019 May; 110(5):1771-1779. PubMed ID: 30887605
[TBL] [Abstract][Full Text] [Related]
23. The Effect of Diagnostic Ureterorenoscopy on Intravesical Recurrence in Patients Undergoing Nephroureterectomy for Primary Upper Tract Urinary Carcinoma.
İzol V; Deger M; Ozden E; Bolat D; Argun B; Baltaci S; Celik O; Akgul HM; Tinay İ; Bayazit Y;
Urol Int; 2021; 105(3-4):291-297. PubMed ID: 33264798
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic predictive value of Xpert Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer.
D Elia C; Pycha A; Folchini DM; Mian C; Hanspeter E; Schwienbacher C; Vjaters E; Pycha A; Trenti E
J Clin Pathol; 2019 Feb; 72(2):140-144. PubMed ID: 30355587
[TBL] [Abstract][Full Text] [Related]
25. Consultation on UTUC II Stockholm 2022: diagnostics, prognostication, and follow-up-where are we today?
Sydén F; Baard J; Bultitude M; Keeley FX; Rouprêt M; Thomas K; Axelsson TA; Jaremko G; Jung H; Malm C; Proietti S; Osther PJS; Brehmer M
World J Urol; 2023 Dec; 41(12):3395-3403. PubMed ID: 37540248
[TBL] [Abstract][Full Text] [Related]
26. Bladder Epicheck Test: A Novel Tool to Support Urothelial Carcinoma Diagnosis in Urine Samples.
Fiorentino V; Pizzimenti C; Franchina M; Rossi ED; Tralongo P; Carlino A; Larocca LM; Martini M; Fadda G; Pierconti F
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569864
[TBL] [Abstract][Full Text] [Related]
27. Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma.
Petros FG; Choi W; Qi Y; Moss T; Li R; Su X; Guo CC; Czerniak B; Dinney C; McConkey DJ; Matin SF
J Urol; 2021 Sep; 206(3):548-557. PubMed ID: 33881933
[TBL] [Abstract][Full Text] [Related]
28. Positioning the role of urine cytology within the diagnostic pathway for UTUC: supportive but inconclusive.
Figaroa OJA; Hendriks N; Kamphuis GM; van Moorselaar RJA; Bins AD; Baard J
World J Urol; 2023 Dec; 41(12):3429-3435. PubMed ID: 37987866
[TBL] [Abstract][Full Text] [Related]
29. Fluorodeoxyglucose positron emission tomography/computed tomography for diagnosis of upper urinary tract urothelial carcinoma.
Asai S; Fukumoto T; Tanji N; Miura N; Miyagawa M; Nishimura K; Yanagihara Y; Shirato A; Miyauchi Y; Kikugawa T; Yokoyama M
Int J Clin Oncol; 2015 Oct; 20(5):1042-7. PubMed ID: 25794920
[TBL] [Abstract][Full Text] [Related]
30. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer.
D'Andrea D; Soria F; Zehetmayer S; Gust KM; Korn S; Witjes JA; Shariat SF
BJU Int; 2019 Jun; 123(6):959-967. PubMed ID: 30653818
[TBL] [Abstract][Full Text] [Related]
32. Consultation on UTUC, Stockholm 2018 aspects of risk stratification: long-term results and follow-up.
Hasan MN; Rouprêt M; Keeley F; Cracco C; Jones R; Straub M; Traxer O; Osther PJS; Brehmer M
World J Urol; 2019 Nov; 37(11):2289-2296. PubMed ID: 30944969
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic accuracy of computed tomography urography and visual assessment during ureterorenoscopy in upper tract urothelial carcinoma.
Grahn A; Melle-Hannah M; Malm C; Jäderling F; Radecka E; Beckman M; Brehmer M
BJU Int; 2017 Feb; 119(2):289-297. PubMed ID: 27611622
[TBL] [Abstract][Full Text] [Related]
34. Comparison of urine cytology and fluorescence in situ hybridization in upper urothelial tract samples.
Reynolds JP; Voss JS; Kipp BR; Karnes RJ; Nassar A; Clayton AC; Henry MR; Sebo TJ; Zhang J; Halling KC
Cancer Cytopathol; 2014 Jun; 122(6):459-67. PubMed ID: 24604675
[TBL] [Abstract][Full Text] [Related]
35. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update.
Rouprêt M; Babjuk M; Compérat E; Zigeuner R; Sylvester RJ; Burger M; Cowan NC; Böhle A; Van Rhijn BW; Kaasinen E; Palou J; Shariat SF
Eur Urol; 2015 Nov; 68(5):868-79. PubMed ID: 26188393
[TBL] [Abstract][Full Text] [Related]
36. Patients with a negative cystoscopy and negative Nmp22® Bladderchek® test are at low risk of missed transitional cell carcinoma of the bladder: a prospective evaluation.
Terrell JD; Elias KJ; Sagalowsky AI; Lotan Y
Int Braz J Urol; 2011; 37(6):706-11. PubMed ID: 22234001
[TBL] [Abstract][Full Text] [Related]
37. Ureteroscopic and extirpative treatment of upper urinary tract urothelial carcinoma: a 15-year comprehensive review of 160 consecutive patients.
Grasso M; Fishman AI; Cohen J; Alexander B
BJU Int; 2012 Dec; 110(11):1618-26. PubMed ID: 22458598
[TBL] [Abstract][Full Text] [Related]
38. Surveillance of upper urinary tract transitional cell carcinoma: the role of ureteroscopy, retrograde pyelography, cytology and urinalysis.
Chen GL; El-Gabry EA; Bagley DH
J Urol; 2000 Dec; 164(6):1901-4. PubMed ID: 11061876
[TBL] [Abstract][Full Text] [Related]
39. Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma.
Simon CT; Skala SL; Weizer AZ; Ambani SN; Chinnaiyan AM; Palapattu G; Hafez K; Magers MJ; Kaffenberger SD; Spratt DE; Montgomery JS; Morgan TM; Udager AM; Lew M; Mehra R
Hum Pathol; 2019 Apr; 86():76-84. PubMed ID: 30537495
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer.
Gilbert SM; Veltri RW; Sawczuk A; Shabsigh A; Knowles DR; Bright S; O'Dowd GJ; Olsson CA; Benson MC; Sawczuk IS
Urology; 2003 Mar; 61(3):539-43. PubMed ID: 12639642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
